Contact Information
37 Westminster Buildings, Theatre Square,
Nottingham, NG1 6LG
Ozempic Settles the Obesity Debate: It's Biology Over Willpower
Weight-loss drugs affect the brain in ways that help researchers understand how the body regulates weight. Source link
Weight-Loss Drug Wegovy Cuts Heart Risk in New Study
Novo Nordisk’s anti-obesity drug reduced people’s risk of suffering heart attacks, strokes and cardiovascular deaths by 20%. Source link
Drugs Like Ozempic Created a Gold Rush. These Drugmakers Want In.
Companies developing weight-loss drugs have raised or made deals valued at more than $1.4 billion since about a year ago. Source link
Eli Lilly to Acquire Versanis Bio, Maker of Obesity Treatment
Versanis shareholders could receive as much as $1.925 billion in cash, which will consist of an upfront payment and additional payments if certain milestones are
Lilly to buy Versanis for up to $1.93 billion to boost obesity drug portfolio By Reuters
© Reuters. FILE PHOTO: Eli Lilly logo is shown on one of the company’s offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File
Obesity Drugs Won't Starve These Other Potential Blockbusters
Stocks of developers of fatty liver disease treatments had been on a tear until results from Eli Lilly’s medication were published last week. Source link
Demand for Obesity Drugs Has Insurers Paying Close Attention
Markets Heard on the Street Strong sales of obesity-diabetes drugs known as GLP-1s could affect insurance companies’ financial results Source link
WeightWatchers Gets a Makeover With Obesity-Drug Business
Markets Heard on the Street The decision to get into the business for drugs such as Ozempic makes sense Source link
The 'King Kong' of Weight-Loss Drugs Is Coming
Eli Lilly’s Mounjaro could outpace Ozempic as the most powerful treatment on the market. To develop it, the drug company needed to overhaul long-held but
